Deepika Jalota Sells 33,065 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Get Free Report) insider Deepika Jalota sold 33,065 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total value of $35,048.90. Following the sale, the insider directly owned 89,959 shares of the company's stock, valued at approximately $95,356.54. This trade represents a 26.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

PMV Pharmaceuticals Stock Up 10.0%

Shares of PMVP traded up $0.11 on Friday, reaching $1.21. The stock had a trading volume of 582,828 shares, compared to its average volume of 197,220. The firm has a market capitalization of $62.86 million, a PE ratio of -1.03 and a beta of 1.49. The firm has a 50-day moving average of $0.99 and a 200 day moving average of $1.18. PMV Pharmaceuticals, Inc. has a twelve month low of $0.81 and a twelve month high of $1.82.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. On average, sell-side analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a report on Thursday, March 20th.

Institutional Investors Weigh In On PMV Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of PMV Pharmaceuticals by 2,282.8% during the fourth quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company's stock worth $37,000 after purchasing an additional 23,559 shares in the last quarter. Velan Capital Investment Management LP purchased a new position in PMV Pharmaceuticals in the fourth quarter valued at about $53,000. Squarepoint Ops LLC boosted its holdings in PMV Pharmaceuticals by 68.7% in the fourth quarter. Squarepoint Ops LLC now owns 73,015 shares of the company's stock valued at $110,000 after purchasing an additional 29,722 shares during the last quarter. Northern Trust Corp boosted its holdings in PMV Pharmaceuticals by 23.2% in the fourth quarter. Northern Trust Corp now owns 107,340 shares of the company's stock valued at $162,000 after purchasing an additional 20,190 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in PMV Pharmaceuticals by 44.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company's stock valued at $305,000 after purchasing an additional 62,200 shares during the last quarter. Hedge funds and other institutional investors own 90.20% of the company's stock.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.